Week 2 Symptomatic Response with Vedolizumab as a Predictive Factor in Japanese Anti-TNFα-Naive Patients with Ulcerative Colitis: A post hoc Analysis of a Randomized, Placebo-Controlled Phase 3 Trial
Open Access
- 15 January 2021
- journal article
- research article
- Published by S. Karger AG in Digestion
- Vol. 102 (5), 742-752
- https://doi.org/10.1159/000512235
Abstract
Background and Aim: To evaluate the onset of symptomatic response with vedolizumab in patients with moderate-to-severe ulcerative colitis in Japan. Methods: Patients were randomized to receive vedolizumab 300 mg or placebo at Weeks 0, 2, and 6. Mayo subscores were analyzed in patients with baseline stool frequency (SF) ≥1 and rectal bleeding (RB) ≥1. In patients with baseline SF ≥2 and RB ≥1, the proportion who achieved SF ≤1 and RB = 0 was determined. Results: Patients were randomized to vedolizumab (n = 164) or placebo (n = 82). Decrease from baseline in mean SF subscore was greater with vedolizumab versus placebo from Week 2 (−6.6%; 95% confidence interval [CI], −16.2, 3.0), with a greater difference in anti-tumor necrosis factor (TNF)α-naive patients (vedolizumab vs. placebo, −13.2%; 95% CI, −29.7, 3.3). Mean percentage decrease from baseline RB subscore was numerically greater with vedolizumab versus placebo from Week 6 in anti-TNFα-naive patients (−10.7%; 95% CI, −33.0, 11.5). More patients in the anti-TNFα-naive subgroup achieved SF ≤1 and RB = 0 with vedolizumab versus placebo at Week 2 (14.8%; 95% CI, 2.5, 27.0) and Week 6 (20.3%; 95% CI, 4.4, 36.2). Patients with SF ≤1 and RB = 0 at Week 2 had higher clinical response, clinical remission, and mucosal healing rates at Week 10 than those without. Conclusions: Our results indicate that vedolizumab induces a rapid symptomatic response, particularly in anti-TNFα-naive patients, and suggest that early symptomatic improvement predicts treatment response at Week 10 (NCT02039505).Keywords
This publication has 19 references indexed in Scilit:
- Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2016
- Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trialsAlimentary Pharmacology & Therapeutics, 2015
- Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-TargetThe American Journal of Gastroenterology, 2015
- Patient-Reported Outcomes as Primary End Points in Clinical Trials of Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2014
- Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: Rapid symptom resolution and improvements in quality of lifeJournal of Crohn's and Colitis, 2014
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative ColitisThe New England Journal of Medicine, 2013
- CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trialsInternational Journal of Surgery, 2012
- Randomised clinical trial: early assessment after 2 weeks of high-dose mesalazine for moderately active ulcerative colitis - new light on a familiar questionAlimentary Pharmacology & Therapeutics, 2011
- Treatment of ulcerative colitis from the patient’s perspective: a survey of preferences and satisfaction with therapyAlimentary Pharmacology & Therapeutics, 2009
- A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative ColitisGastroenterology, 2007